A new medication from AbbVie for hepatitis C is in the testing stage.
The US Food and Drug Administration (FDA) has given AbbVie a breakthrough therapy designation for an investigational pan-genotypic drug regimen that the drugmaker is currently developing to treat hepatitis C, the company announced.
Breakthrough therapy designation by the FDA serves to accelerate the review process. It is granted to investigational drugs that treat serious or life-threatening conditions with preliminary clinical evidence that demonstrate substantial improvement over existing therapies, stated an AbbVie release.
The company said it was given the FDA designation based on results from its phase 2 clinical trial for patients with genotype 1 hepatitis C virus whose previous therapy attempts with direct-acting antiviral drugs were unsuccessful.
|Read Full Article: AbbVie Gets Breakthrough Therapy Designation to Test Pan-genotypic Hepatitis C Drug|